Dr. Ihsan Al-Khalil, MD

Media Releases

Get to know Pediatric Hematologist-Oncologist Dr. Ihsan Al-Khalil, who serves patients in Lumberton, North Carolina.

Dr. Al-Khalil is a fellowship-trained pediatric hematologist-oncologist with over five decades of experience in his field. He sees patients at Southeastern Family Medicine Residency Clinic in Lumberton, North Carolina.

With an unwavering commitment to his speciality, he is board-certified in pediatrics and pediatric hematology-oncology by the American Board of Pediatrics (ABP). The mission of the ABP is to advance child health by certifying pediatricians who meet standards of excellence and are committed to continuous learning and improvement.

A 1972 graduate of the University of Damascus, Faculty of Medicine in Syria, Dr. Al-Khalil relocated to the United States to complete his training. He performed his internship at Iowa Methodist Medical Center and his residency in pediatrics at the Medical College of Ohio at Toledo. Wanting to further his education, he completed his fellowships in pediatric hematology-oncology at the University of Connecticut and Yale-New Haven Hospital.

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease. More specifically, a pediatric hematologist-oncologist treats children and teens from birth through young adulthood.

Among the doctor’s most notable achievements, he is the recipient of Patients’ Choice Award (2016, 2017) and Compassionate Doctor Recognition (2016, 2017).

Recommended Articles

• Exercise Proven to Help Lymphoma Patients

  People always say that exercise is the best medicine. It's been proven through many years of research that regular exercise is really important to maintain a healthy body and mind. Doctors are always reminding their patients of the benefits of physical exercise and the power it holds to fight...

• How Dogs Are Helping with Lymphoma Research

  According to the Cornell Chronicle (CC), Cornell and Tufts University have received a huge grant for the study of human lymphoma, using a humane approach to test on dogs.The dogs in the study will already have lymphoma and it’s hoped they’ll be cured in the process of this research study.There...

• Stanford University's Linebacker Ryan Beecher Must Now Tackle Lymphoma

  There's no doubt that Ryan Beecher is strong. If you want just watch one Stanford University football game, you'll see that and then some. However, he is now going to have to use a different type of strength in his battle against lymphoma.Ryan's storyWhile many had been following Ryan Beecher before...

• Teen with Hodgkin Lymphoma Skates with Her Hero, Mario Lemieux

  Lillian Tarasiewicz was diagnosed with stage 3B Hodgkin lymphoma in October of 2015. She currently resides in South Carolina, but because of her father’s Pennsylvania background, she grew up with a love for hockey and for the Pittsburgh Penguins. She always felt a special connection to Mario...

• Astonishing Clinical Trial Results Show Promise for Non-Hodgkin Lymphoma Research

  There’s good news for those who’ve been diagnosed with the aggressive non-Hodgkin lymphoma (NHL) type referred to as diffuse large-B cell (DLBCL). According to the American Cancer Society (ACS), this type of HNL is the most common type of lymphoma.The descriptive letters clarify the type of...

• Treatment Update for Hodgkin Lymphoma

  Over time, research has uncovered ways of treating Hodgkin lymphoma (HL) to produce an 80% to 90% cure rate. For the remaining 10% to 20% who are either resistant to the primary treatment or have relapsed, their cancer can still be fatal.The standard care for those not yet cured has been a two-step...